 During July, Calliditas Therapeutics AB publ has issued 706,676 common shares as a result of the exercise of the over-allotment option within the initial public offering on The Nasdaq Global Select Market and the concurrent private placement of common shares to certain qualified investors in Europe and certain other jurisdictions outside of the United States. Further, during July, warrants within the companys warrant program issued in 2017 have been converted to 1,185,250 common shares. Thus, as of July 31, 2020, the number of shares and votes in the company amounts to 49,830,334. 